Theravance Biopharma Inc. (TBPH)

Trade TBPH now with
12/23/2019 8:17:58 AM Theravance Biopharma, Pfizer Enter Global License Deal For Skin-Targeted, Locally-Acting Pan-JAK Inhibitor Program
12/3/2019 7:54:21 AM Theravance Biopharma Announces Dosing Of First Patient In Phase 2 Allergen Challenge Study Of TD-8236
9/9/2019 7:06:59 AM Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial Of TD-8236
7/31/2019 7:25:17 AM Theravance Biopharma Q2 Net Loss $39.8 Mln Vs. Net Loss $40.8 Mln Last Year
7/22/2019 8:20:49 AM Theravance Biopharma Reports New Data From Phase 2 Study Of Ampreloxetine At 32nd European Neurology Congress
6/18/2019 9:19:19 AM Theravance Reports Data From Phase 2 Study Of Ampreloxetine; Data Supports Phase 3 Program In Symptomatic NOH
6/14/2019 8:12:44 AM Theravance Biopharma, Mylan Expand YUPELRI Development, Commercialization Agreement
6/4/2019 8:31:26 AM Theravance Biopharma Appoints Andrew Hindman As SVP And CFO
5/21/2019 7:05:51 AM Theravance Biopharma Reports Data From Phase 1b Study Of TD-1473 In Oral Presentation At DDW 2019
5/20/2019 10:16:31 AM Theravance Biopharma And Mylan Present Additional YUPELRI Phase 3 Data Analysis
3/25/2019 8:35:03 AM Theravance Biopharma: TD-9855 Phase 2 Study Results Selected For Oral Presentation At 32nd European Neurology Congress
3/12/2019 8:32:09 AM Theravance Biopharma Doses First Patient In Phase 2b/3 Study Of TD-1473
2/26/2019 4:18:49 PM Theravance Biopharma Q4 Loss/share $0.92 Vs. Loss $1.64 Year Ago
1/28/2019 8:35:51 AM Theravance : First Patient Dosed In Registrational Phase 3 Study Of Ampreloxetine For The Treatment Of Symptomatic NOH
12/13/2018 7:30:47 AM Jeff Jonker Joins Ambys Medicines As President And CEO
11/27/2018 7:56:08 AM Theravance Announces First Subject Dosed In Phase 1 Trial Of TD-8236, A Novel Inhaled Pan-JAK Inhibitor
11/20/2018 8:35:27 AM Theravance Announces First Patient Dosed In Phase 2 Study Of TD-1473 In Patients With Crohn's Disease